Diagnostic Imaging Partnering Terms and Agreements - NBC Right Now/KNDO/KNDU Tri-Cities, Yakima, WA |

Diagnostic Imaging Partnering Terms and Agreements

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Diagnostic Imaging Partnering Terms and Agreements

https://www.reportbuyer.com/product/2276222/Diagnostic-Imaging-Partnering-Terms-and-Agreements.html

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:

Imaging
CT
Endoscope
Molecular and nuclear
PET
SPECT
MRI
Ultrasound
X ray
Angiography
Fluoroscopy
Mammography

This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2009.

This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2009. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.

Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.

For example, analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostic imaging dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading diagnostic imaging deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of diagnostic imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of diagnostic imaging partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of diagnostic imaging partnering deals by specific imaging technology types announced since 2009. The chapter is categorized by deals including imaging, CT, Endoscope, Molecular and nuclear (PET, SPECT), MRI, Ultrasound, X-Ray (angiography, fluoroscopy, mammography). Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in diagnostic imaging partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by diagnostic imaging partnering by company A-Z , stage of development, deal type and therapy area. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostic imaging technologies and products.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.
Diagnostic Imaging Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to diagnostic imaging trends and structure of deals entered into by leading companies worldwide.

Diagnostic Imaging Partnering Terms and Agreements includes:

Trends in diagnostic imaging dealmaking in the biopharma industry since 2009
Analysis of diagnostic imaging deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life diagnostic imaging deals
Access to over 700 diagnostic imaging deal documents
The leading vaccine deals by value since 2009
Most active diagnostic imaging dealmakers since 2009
The leading diagnostic imaging partnering resources

In Diagnostic Imaging Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Therapy target
Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise vaccine rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in diagnostic imaging dealmaking

2.1. Introduction
2.2. Diagnostic imaging partnering over the years
2.3. Big pharma diagnostic imaging dealmaking activity
2.4. Most active in diagnostic imaging partnering
2.5. Diagnostic imaging partnering by industry sector
2.6. Diagnostic imaging partnering by deal type
2.7. Diagnostic imaging partnering by disease type
2.8. Diagnostic imaging partnering by specific technology type
2.9. Average deal terms for diagnostic imaging partnering
2.9.1 Diagnostic imaging headline values
2.9.2 Diagnostic imaging upfront payments
2.9.3 Diagnostic imaging milestone payments
2.9.4 Diagnostic imaging royalty rates
2.10. The anatomy of diagnostic imaging partnering
2.10. The anatomy of a diagnostic imaging deal
2.10.a. Case study : Vaso Diagnostics- GE Healthcare: July 2010

Chapter 3 – Leading diagnostic imaging deals

3.1. Introduction
3.2. Top diagnostic imaging deals by value

Chapter 4 – Big pharma diagnostic imaging deals

4.1. Introduction
4.2. How to use big pharma diagnostic imaging partnering deals
4.3. Big pharma diagnostic imaging partnering company profiles
Abbott
Actavis (acquired by Watson)
AstraZeneca
Bayer
Eisai
Eli Lilly
GlaxoSmithKline
Lundbeck
Merck & Co
Merck KGaA
Novartis
Roche
Sanofi
Servier

Chapter 5 – Diagnostic imaging partnering contracts directory

5.1. Introduction

5.2. Company A-Z

Actavis (acquired by Watson)
Acusphere
Audeo Oncology
Beijing Double-Crane Pharmaceutical
Bio-Imaging Technologies
BioClinica
Biofield
Biotage
Caliper Life Sciences
Cantel Medical (UK)
Cryolife
Dr Faupel
Esaote
GE Healthcare
General Electric (GE)
Guided Therapeutics
IsoRay
Konica Minolta
Lantheus Medical Imaging
MDS Nordion
Misonix
Norgine
Novel Laboratories
Pharmalucence
Salix Pharmaceuticals
Siemens
SonoSite
Starch Medical
SurgiVision
Techniscan
USHIFU
Vaso Diagnostics
Vasomedical

5.3. By deal type

Asset purchase
Co-development
Contract service
Development
Distribution
Licensing
Manufacturing
Marketing
Option
Promotion
Settlement
Sub-license
Supply
Technology transfer
Termination

5.4. By stage of development

Preclinical
Phase III
Regulatory
Marketed
5.5. By therapy area
Cardiovascular
Dermatology
Gastrointestinal
Hematology
Hospital care
Oncology

Chapter 6 – Diagnostic imaging dealmaking by specific imaging type

6.1. Introduction
6.2. Deals by diagnostic imaging type

Appendices

Introduction
Appendix 1 – Directory of diagnostic imaging deals by company A-Z 2009 to 2014
Appendix 2 – Directory of diagnostic imaging deals by stage of development 2009 to 2014
Appendix 3 – Directory of diagnostic imaging deals by deal type 2009 to 2014
Appendix 4 – Directory of diagnostic imaging deals by therapy area 2009 to 2014
Appendix 5 – Diagnostic Imaging partnering resource center
Online diagnostic imaging partnering
Diagnostic Imaging partnering events
Further reading on diagnostic imaging dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Technology Reports
Order Form – Upgrades to subscription access products

Table of figures

Figure 1: Diagnostic imaging partnering since 2009
Figure 2: Big pharma – top 50 – Diagnostic imaging deals 2009 to 2014
Figure 3: Big pharma diagnostic imaging deal frequency – 2009 to 2014
Figure 4: Active diagnostic imaging dealmaking activity– 2009 to 2014
Figure 5: Diagnostic imaging partnering by industry sector since 2009
Figure 6: Diagnostic imaging partnering by deal type since 2009
Figure 7: Diagnostic imaging partnering by disease type since 2009
Figure 8: Diagnostic imaging partnering by disease type since 2009
Figure 9: Diagnostic imaging deals with a headline value
Figure 10: Diagnostic imaging deal headline value distribution, US$million – discovery stage
Figure 11: Diagnostic imaging deal headline value distribution, US$million – preclinical stage
Figure 12: Diagnostic imaging deal headline value distribution, US$million – phase I stage
Figure 13: Diagnostic imaging deal headline value distribution, US$million – phase II stage
Figure 14: Diagnostic imaging deal headline value distribution, US$million – phase III stage
Figure 15: Diagnostic imaging deal headline value distribution, US$million – regulatory stage
Figure 16: Diagnostic imaging deal headline value distribution, US$million – marketed stage
Figure 17: Summary median headline value by stage of development, 2009-2014
Figure 18: Diagnostic imaging deals with upfront payment values
Figure 19: Diagnostic imaging deal upfront payment distribution, US$million – discovery stage
Figure 20: Diagnostic imaging deal upfront payment distribution, US$million – preclinical stage
Figure 21: Diagnostic imaging deal upfront payment distribution, US$million – phase I stage
Figure 22: Diagnostic imaging deal upfront payment distribution, US$million – phase II stage
Figure 23: Diagnostic imaging deal upfront payment distribution, US$million – phase III stage
Figure 24: Diagnostic imaging deal upfront payment distribution, US$million – regulatory stage
Figure 25: Diagnostic imaging deal upfront payment distribution, US$million – marketed stage
Figure 26: Summary median upfront payments by stage of development, 2009-2014
Figure 27: Diagnostic imaging deals with milestone payments
Figure 28: Diagnostic imaging deal milestone distribution, US$million – discovery stage
Figure 29: Diagnostic imaging deal milestone distribution, US$million – preclinical stage
Figure 30: Diagnostic imaging deal milestone distribution, US$million – phase I stage
Figure 31: Diagnostic imaging deal milestone distribution, US$million – phase II stage
Figure 32: Diagnostic imaging deal milestone distribution, US$million – phase III stage
Figure 33: Diagnostic imaging deal milestone distribution, US$million – regulatory stage
Figure 34: Diagnostic imaging deal milestone distribution, US$million – marketed stage
Figure 35: Diagnostic imaging deals with royalty rates, %
Figure 36: Diagnostic imaging deal royalty rate distribution, US$million – discovery stage
Figure 37: Diagnostic imaging deal royalty rate distribution, US$million – preclinical stage
Figure 38: Diagnostic imaging deal royalty rate distribution, US$million – phase I stage
Figure 39: Diagnostic imaging deal royalty rate distribution, US$million – phase II stage
Figure 40: Diagnostic imaging deal royalty rate distribution, US$million – phase III stage
Figure 41: Diagnostic imaging deal royalty rate distribution, US$million – regulatory stage
Figure 42: Diagnostic imaging deal royalty rate distribution, US$million – marketed stage
Figure 43: Summary median royalty rate by stage of development, 2009-2014
Figure 44: Components of the typical diagnostic imaging deal structure
Figure 45: Top diagnostic imaging deals by value since 2009
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events

Read the full report:
Diagnostic Imaging Partnering Terms and Agreements

https://www.reportbuyer.com/product/2276222/Diagnostic-Imaging-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KHQ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.